LU Bioscience increases position in ProNoxis
"I value the progress made in ProNoxis" says Thomas Andersson, CEO of LU Bio. "We closely monitor the achievements and progress in our portfolio companies in order to successfully build our investment company within the field of bioscience."
ProNoxis is a spin out company from Redoxis and is focused on developing anti-inflammatory therapeutics that act through the NADPH oxidase complex (NOX2), an invention based on the research by Prof Rikard Holmdahl and Dr Peter Olofsson.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.